Zonghua Luo

Zonghua Luo

Auto-generated profile, based on publicly available information

Zonghua Luo

Department of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ZLZonghua Luo
Zonghua Luo
ARAdam Rosenberg
Adam Rosenberg
HLHui Liu
Hui Liu
JHJunbin Han
Junbin Han
ZTZhude Tu
Zhude Tu

15 November 2018 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
ZLZonghua Luo
Zonghua Luo
JHJunbin Han
Junbin Han
HLHui Liu
Hui Liu
ARAdam Rosenberg
Adam Rosenberg
DCDelphine L. Chen
Delphine L. Chen
ZTZhude Tu
Zhude Tu
A series of seventeen hydroxyl-containing sphingosine 1-phosphate receptor 1 (S1PR1) ligands were designed and synthesized. Their in vitro binding potencies were determined using [32P]S1P competitive binding assays. Compounds 10a, 17a, 17b, and 24 exhibited high S1PR1 binding potencies with IC50 values ranging from 3.9 to 15.4 nM and also displayed high selectivity for S1PR1 over other S1P receptor subtypes (IC50 > 1000 nM for S1PR2–5). The most potent compounds 10a, 17a, 17b, and 24 were subsequently radiolabeled with F-18 in high yields and purities. MicroPET studies in cynomolgus macaque showed that [18F]10a, [18F]17a, and [18F]17b but not [18F]24 crossed the blood brain barrier and had high initial brain uptake. Further validation of [18F]10a, [18F]17a, and [18F]17b in preclinical models of neuroinflammation is warranted to identify a suitable PET radioligand to quantify S1PR1 expression in vivo as a metric of an inflammatory response.

6 December 2017 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
ZLZonghua Luo
Zonghua Luo
XYXuyi Yue
Xuyi Yue
HYHao Yang
Hao Yang
HLHui Liu
Hui Liu
RKRobyn S. Klein
Robyn S. Klein
ZTZhude Tu
Zhude Tu

9 May 2019 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
YYYanbo Yu
Yanbo Yu
QLQianwa Liang
Qianwa Liang
HLHui Liu
Hui Liu
ZLZonghua Luo
Zonghua Luo
HHHongzheng Hu
Hongzheng Hu
ZTZhude Tu
Zhude Tu
The transient receptor potential channel subfamily member 5 (TRPC5) is a calcium permeable cation channel widely expressed in the brain. Accumulating evidence indicates that it plays a crucial role in psychiatric disorders including depression and anxiety. Positron emission tomography (PET) combined with a TRPC5 specific radioligand may provide a unique tool to investigate the functions of TRPC5 in animal disease models to guide drug development targeting TRPC5. To develop a TRPC5 PET radiotracer, the potent TRPC5 inhibitor HC608 was chosen for C-11 radiosynthesis through the N-demethyl amide precursor 7 reacting with [11C]methyl iodide. Under optimized conditions, [11C]HC608 was achieved with good radiochemical yield (25 ± 5%), high chemical and radiochemical purity (>99%), and high specific activity (204–377 GBq μmol−1, decay corrected to the end of bombardment, EOB). The in vitro autoradiography study revealed that [11C]HC608 specifically binds to TRPC5. Moreover, initial in vivo evaluation of [11C]HC608 performed in rodents and the microPET study in the brain of non-human primates further demonstrated that [11C]HC608 was able to penetrate the blood brain barrier and sufficiently accumulate in the brain. These results suggest that [11C]HC608 has the potential to be a PET tracer for imaging TRPC5 in vivo.

30 May 2017 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
XYXuyi Yue
Xuyi Yue
HJHongjun Jin
Hongjun Jin
HLHui Liu
Hui Liu
ZLZonghua Luo
Zonghua Luo
XZXiang Zhang
Xiang Zhang
ZTZhude Tu
Zhude Tu
The vesicular acetylcholine transporter (VAChT) is a reliable biomarker for assessing cholinergic dysfunction associated with dementia. We recently reported three new potent and selective carbon-11 labeled VAChT radiotracers. Herein, we report the resolution with a Chiralcel OD column of three additional fluorine containing VAChT ligands in which a fluoroethoxy or fluoroethylamino moiety was substituted for the methoxy group. An in vitro competitive binding assay showed that (−)-7 had high potency for VAChT (Ki-VAChT = 0.31 ± 0.03 nM) and excellent selectivity for VAChT versus σ receptors (K i-σ1 = 1870 ± 250 nM, K i-σ2 = 5480 ± 140 nM). Three different radiolabeling approaches were explored; the radiosynthesis of (−)-[18F]7 was successfully accomplished via a stepwise two-pot, three-step method with moderate yield (11 ± 2%) and high radiochemical purity (>98%). PET imaging studies in a nonhuman primate indicated that (−)-[18F]7 rapidly entered the brain and accumulated in the VAChT-enriched striatum. The uptake of (−)-[18F]7 in the target striatal area peaked at 10 min and displayed improved clearance kinetics compared to the VAChT tracer [18F]VAT, which has been approved by the Food and Drug Administration (FDA) for first-in-man studies. These studies justify further investigation of (−)-[18F]7 and exploration of the structure–activity relationships of these fluoroethoxy and fluoroethylamino analogs.

19 August 2018 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
ZLZonghua Luo
Zonghua Luo
HLHui Liu
Hui Liu
HJHongjun Jin
Hongjun Jin
JGJiwei Gu
Jiwei Gu
YYYanbo Yu
Yanbo Yu
ZTZhude Tu
Zhude Tu